ACTA1 and cancer: Nevertheless, reducing myCAF by targeting α-SMA in the tumor led to reduced survival rates in both humans and mice, due to the duality of extensive ECM protein deposition as an immune-physical barrier, restricting immune cell accessibility to cancer cells, but simultaneously restricting tumor growth to an extent10.